Raymond James Trust N.A. Has $36.68 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Raymond James Trust N.A. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 226,343 shares of the company’s stock after purchasing an additional 8,849 shares during the period. Johnson & Johnson makes up 0.8% of Raymond James Trust N.A.’s investment portfolio, making the stock its 24th biggest holding. Raymond James Trust N.A.’s holdings in Johnson & Johnson were worth $36,681,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Concorde Asset Management LLC increased its holdings in Johnson & Johnson by 2.5% during the 3rd quarter. Concorde Asset Management LLC now owns 5,010 shares of the company’s stock worth $812,000 after purchasing an additional 124 shares in the last quarter. Eagle Asset Management Inc. boosted its position in shares of Johnson & Johnson by 22.1% during the third quarter. Eagle Asset Management Inc. now owns 57,612 shares of the company’s stock valued at $8,957,000 after buying an additional 10,439 shares during the last quarter. Activest Wealth Management purchased a new stake in Johnson & Johnson in the 3rd quarter valued at $40,000. Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after acquiring an additional 102,502 shares in the last quarter. Finally, Smithfield Trust Co boosted its holdings in Johnson & Johnson by 5.2% during the 3rd quarter. Smithfield Trust Co now owns 86,490 shares of the company’s stock worth $14,006,000 after acquiring an additional 4,274 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Citigroup lifted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Morgan Stanley increased their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.94.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 1.8 %

JNJ stock opened at $155.79 on Friday. The stock has a 50-day simple moving average of $160.41 and a two-hundred day simple moving average of $156.17. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The firm has a market capitalization of $375.08 billion, a PE ratio of 22.55, a PEG ratio of 2.72 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.66 EPS. On average, equities analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.